Cited Articles for PMCID: 3644999

Year	Number of Results
1999	1
2000	2
2004	2
2005	4
2006	5
2007	2
2008	2
2009	7
2010	10
2011	10
2012	5
2024	0

1

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA. Cooper SJ, et al. Mol Cancer Ther. 2012 Oct;11(10):2105-15. doi: 10.1158/1535-7163.MCT-11-0873. Epub 2012 Jul 23. Mol Cancer Ther. 2012. PMID: 22826467 Free PMC article.

2

State of the science: an update on renal cell carcinoma.

Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. Jonasch E, et al. Mol Cancer Res. 2012 Jul;10(7):859-80. doi: 10.1158/1541-7786.MCR-12-0117. Epub 2012 May 25. Mol Cancer Res. 2012. PMID: 22638109 Free PMC article. Review.

3

SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids.

Mason P, Liang B, Li L, Fremgen T, Murphy E, Quinn A, Madden SL, Biemann HP, Wang B, Cohen A, Komarnitsky S, Jancsics K, Hirth B, Cooper CG, Lee E, Wilson S, Krumbholz R, Schmid S, Xiang Y, Booker M, Lillie J, Carter K. Mason P, et al. PLoS One. 2012;7(3):e33823. doi: 10.1371/journal.pone.0033823. Epub 2012 Mar 22. PLoS One. 2012. PMID: 22457791 Free PMC article.

4

Current treatment considerations in metastatic renal cell carcinoma.

Haddad H, Rini BI. Haddad H, et al. Curr Treat Options Oncol. 2012 Jun;13(2):212-29. doi: 10.1007/s11864-012-0182-8. Curr Treat Options Oncol. 2012. PMID: 22410708 Review.

5

Endoplasmic reticulum stress and lipid metabolism: mechanisms and therapeutic potential.

Basseri S, Austin RC. Basseri S, et al. Biochem Res Int. 2012;2012:841362. doi: 10.1155/2012/841362. Epub 2011 Dec 13. Biochem Res Int. 2012. PMID: 22195283 Free PMC article.

6

The unfolded protein response: from stress pathway to homeostatic regulation.

Walter P, Ron D. Walter P, et al. Science. 2011 Nov 25;334(6059):1081-6. doi: 10.1126/science.1209038. Science. 2011. PMID: 22116877 Review.

7

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Rini BI, et al. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Lancet. 2011. PMID: 22056247 Clinical Trial.

8

Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.

Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM, Wong TW, Rupnow BA. Roongta UV, et al. Mol Cancer Res. 2011 Nov;9(11):1551-61. doi: 10.1158/1541-7786.MCR-11-0126. Epub 2011 Sep 27. Mol Cancer Res. 2011. PMID: 21954435

9

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Coppin C, et al. BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. BJU Int. 2011. PMID: 21952069 Review.

10

Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.

Pinthus JH, Whelan KF, Gallino D, Lu JP, Rothschild N. Pinthus JH, et al. Can Urol Assoc J. 2011 Aug;5(4):274-82. doi: 10.5489/cuaj.10196. Can Urol Assoc J. 2011. PMID: 21801687 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

48 results

Results by year